CDK17 and glioma: Furthermore, genetic data from TCGA datasets show that CDK17 exhibits focal copy number deletions, missense, and frameshift mutations in low-grade glioma (LGG) and glioblastoma (GBM), further supporting its potential as a tumor suppressor in brain cancers (Fig. 4).